TY - JOUR
T1 - Mast cells and cancer
T2 - a review of literature
AU - Paolino, Giovanni
AU - Corsetti, Paola
AU - Moliterni, Elisa
AU - Corsetti, Serena
AU - Didona, Dario
AU - Albanesi, Marcello
AU - Mattozzi, Carlo
AU - Lido, Paolo
AU - Calvieri, Stefano
PY - 2017/11/30
Y1 - 2017/11/30
N2 - Mast cells (MCs) are a potent proangiogenic factor in tumors, they product several pro- angiogenic factors such as fibroblast growth factor 2 (FGF-2), vascular epithelial growth factor (VEGF), tryptase and chymase. Tryptase is a serine protease classified as α-tryptase and β-tryptase, both produced by MCs. Tryptase degrades the tissues, playing an important role in angiogenesis and in the development of metastases. Serum tryptase increases with age, with increased damage to cells and risk of developing a malignancy and it could be considered the expression of a fundamental role of MCs in tumor growth or, on the contrary, in the antitumor response. Many biomarkers have been developed in clinical practice for improving diagnosis and prognosis of some neoplasms. Elevated tryptase levels are found in subgroups of patients with haematologic and solid cancers. In the current review, we want to update the perspectives of tryptase as a potential biomarker in daily practice in different neoplasms.
AB - Mast cells (MCs) are a potent proangiogenic factor in tumors, they product several pro- angiogenic factors such as fibroblast growth factor 2 (FGF-2), vascular epithelial growth factor (VEGF), tryptase and chymase. Tryptase is a serine protease classified as α-tryptase and β-tryptase, both produced by MCs. Tryptase degrades the tissues, playing an important role in angiogenesis and in the development of metastases. Serum tryptase increases with age, with increased damage to cells and risk of developing a malignancy and it could be considered the expression of a fundamental role of MCs in tumor growth or, on the contrary, in the antitumor response. Many biomarkers have been developed in clinical practice for improving diagnosis and prognosis of some neoplasms. Elevated tryptase levels are found in subgroups of patients with haematologic and solid cancers. In the current review, we want to update the perspectives of tryptase as a potential biomarker in daily practice in different neoplasms.
U2 - 10.23736/S0392-0488.17.05818-7
DO - 10.23736/S0392-0488.17.05818-7
M3 - Article
C2 - 29192477
JO - Giornale Italiano di Dermatologia e Venereologia
JF - Giornale Italiano di Dermatologia e Venereologia
SN - 0392-0488
ER -